**Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine- Authors’ reply**

Stephen Walimbwaa, Mohammed Lamordea, Catriona Waittb, Alieu Amarab, Saye Khoob#

a Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda

b Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom

#Address correspondence to khoo@liv.ac.uk

We thank Banda *et al*. for their interest in our study and for suggesting a procedure for handling biologically implausible concentrations. In the study group that investigated the drug-drug interaction between dolutegravir (DTG) and the artemisinin containing therapy (ACTs) artemether-lumefantrine (AL), we reported higher DTG concentrations at 24 hours post-dosing (*C24*) in the period when DTG was administered alone.

We agree with Banda *et al*. in their observation that participants do not perfectly adhere to study protocol instructions. We dispensed exact numbers of pills, monitored adherence by pill count and directly observed the final dose. We investigated the possibility of a dosing error and found nothing to suggest that this had occurred. We recognize that others have reported unexplained peaks in concentration measurements of antiretroviral therapies. For example, Kakuda *et al*. reported higher *C24* in a healthy volunteer study of a fixed-dose combination of darunavir plus cobicistat compared with darunavir and ritonavir as single agents (1). Unexpected peaks may occur due to enterohepatic circulation and by other mechanisms including drug formulation and inter-subject physiological variability (2). Castellino *et al*. report that 33%-48% of the fraction of DTG absorbed in the gastrointestinal tract undergoes enterohepatic recirculation (3).

For these reasons, we felt that the most appropriate approach was to retain all data points in our analyses. However, we have stated (and Banda *et al*. acknowledge), that the statistical difference that we reported is not clinically significant.

**References**

1. Kakuda, T.N., Opsomer, M., Timmers, M., Iterbeke, K., Van De Casteele, T., Hillewaert, V., Petrovic, R. and Hoetelmans, R.M., 2014. Pharmacokinetics of darunavir in fixed‐dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers. The Journal of Clinical Pharmacology, 54(8), pp.949-957.
2. Davies, N.M., Takemoto, J.K., Brocks, D.R. and Yanez, J.A., 2010. Multiple peaking phenomena in pharmacokinetic disposition. Clinical pharmacokinetics, 49(6), pp.351-377.
3. Castellino, S., Moss, L., Wagner, D., Borland, J., Song, I., Chen, S., Lou, Y., Min, S.S., Goljer, I., Culp, A. and Piscitelli, S.C., 2013. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrobial agents and chemotherapy, 57(8), pp.3536-3546.